



FOR IMMEDIATE RELEASE

October 30, 2025

Listed Company Name:	Eisai Co., Ltd.
Representative:	Haruo Naito Representative Corporate Officer and CEO
Securities Code:	4523
Stock Exchange Listings:	Prime Market of the Tokyo Stock Exchange
Inquiries:	Teruyuki Masaka Vice President, Corporate Communications Phone +81-3-3817-5120

Revenue of LEQEMBI® (Preliminary Basis)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI®" (generic name: lecanemab) was JPY 41.1 billion for the first half of fiscal year 2025 (April 1, 2025 – September 30, 2025). By major markets, revenue came to JPY 19.3 billion in the United States, JPY 11.7 billion in Japan, and JPY 7.9 billion in China due to stockpiling by distributors in the first quarter of this fiscal year in response to the risk of tariffs.

This information is being disclosed in conjunction with today's announcement of the financial results for the third quarter of 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai's financial results for the second quarter of fiscal year 2025, including details of LEQEMBI's revenue, will be disclosed in Eisai's financial disclosure scheduled for November 5, 2025.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.
